For Cell And Gene Therapies, Expedited Designation And Complex Questions Improve FDA Meeting Chances

 
• By Sue Sutter
  
Generate a summary of this article
Listen to this article
Beta

Designation as a regenerative medicine advanced therapy or breakthrough therapy ‘dramatically increases’ the likelihood of getting a meeting with the agency, Office of Tissues and Advanced Therapies’ Wilson Bryan says; more complex and innovative products, and more challenging questions, also are likely to win sponsors an audience with the FDA.

Complicated wires
The more complicated the product, the more likely a cell or gene therapy sponsor is to have its meeting request granted by the FDA. • Source: Shutterstock

Developers of cell and gene therapies are more likely to have their meeting requests granted by the US Food and Drug Administration if their product has expedited pathway designation or if the questions at issue are particularly complex, Office of Tissues and Advanced Therapies director Wilson Bryan told the recent annual meeting of the American Society of Gene and Cell Therapy.

If a product is designated under the FDA’s regenerative medicine advanced therapy or breakthrough therapy programs, this “dramatically increases” the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

test carousel-PINKSHEET

 
• By Saba Afreen

test carousel-test

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says - Clone

 
• By Sue Sutter

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Testing all options - Akash

 
• By Akash

This is an test article.

More from Advanced Technologies

CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged

 
• By Sue Sutter

Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.

test

 
• By Sabbah and Saba Afreen

test

Gene Therapies: CoGenT Pilot Could Help With Regulatory Convergence Earlier In Development TEST

 
• By Sue Sutter

Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.